question_id,date,category,question_text,baseline_success,baseline_actually_answered,baseline_has_expected,baseline_confidence,baseline_text,baseline_error,baseline_time,baseline_input_tokens,baseline_output_tokens,togomcp_success,togomcp_has_expected,togomcp_confidence,togomcp_text,togomcp_error,togomcp_time,togomcp_input_tokens,togomcp_output_tokens,togomcp_cache_creation_input_tokens,togomcp_cache_read_input_tokens,tools_used,tool_details,value_add,expected_answer,notes
49,2026-02-01,Structured Query,Find compounds with sub-nanomolar potency against any human protein target.,True,False,False,0.0,,,3.066541910171509,53,3,True,False,0.25,"Based on my comprehensive search of the ChEMBL database, here are **compounds with sub-nanomolar potency (IC50/Ki/Kd < 1 nM)** against human protein targets:

## Top Sub-Nanomolar Compounds

### 1. **Ponatinib** (CHEMBL1171837)
- **Potency**: IC50 = **0.14 pM** (1.427 × 10⁻¹³ nM)
- **Target**: EM-2 (likely a kinase target)
- **Clinical Status**: FDA-approved tyrosine kinase inhibitor for chronic myeloid leukemia
- **Additional targets**: Multiple kinases with IC50 values in the 0.1-0.9 nM range

### 2. **Ditekiren** (CHEMBL1790497)
- **Potency**: IC50 = **0.26 pM** (2.6 × 10⁻¹⁰ nM)
- **Target**: **Renin** (Human - CHEMBL286)
- **Type**: Renin inhibitor developed for hypertension

### 3. **Spiperone** (CHEMBL267930)
- **Potency**: IC50 = **0.3 pM** (3 × 10⁻¹⁰ nM)
- **Target**: **Dopamine D2 receptor** (Human - CHEMBL217)
- **Type**: Potent antipsychotic drug
- **Additional affinity**: Ki values of 0.015-0.8 nM across multiple assays

### 4. **Methotrexate** (CHEMBL34259)
- **Potency**: Ki = **5.6 pM** (5.62 × 10⁻⁹ nM)
- **Target**: **Dihydrofolate reductase** (DHFR)
- **Clinical Status**: FDA-approved anticancer and immunosuppressive drug
- **Additional data**: IC50 = 10-20 pM in some assays

### 5. **Aminopeptidase Inhibitors**
- **CHEMBL1160020**: Ki = **0.6 pM** (6 × 10⁻¹⁰ nM) against Aminopeptidase N
- **CHEMBL1160019**: Ki = **1.5 pM** (1.5 × 10⁻⁹ nM) against Aminopeptidase N

### 6. **Acetylcholinesterase Inhibitors**
Multiple compounds with IC50 = **5 nM** against human acetylcholinesterase (CHEMBL220):
- CHEMBL370807, CHEMBL382260, CHEMBL199748, CHEMBL200008, and ~20 other analogs

### 7. **Additional Notable Compounds**

**R-N-Propylnorapomorphine**
- IC50 = **1 pM** (1 × 10⁻⁹ nM) against Dopamine D2 receptor

**Paclitaxel** (CHEMBL428647)
- IC50 = **20 pM** (2 × 10⁻⁸ nM) against SK-OV-3 cells
- Famous anticancer drug (Taxol)

**Imatinib** (CHEMBL941)
- Ki = **31 pM** (3.08 × 10⁻⁵ nM)
- FDA-approved for CML (Gleevec)

## Summary Statistics

From the ChEMBL database analysis:
- **36,617 Ki values < 1 nM** across all targets
- Top human protein targets with sub-nanomolar inhibitors:
  - Dopamine D2 receptor
  - Acetylcholinesterase  
  - Renin
  - Dihydrofolate reductase
  - Aminopeptidases
  - Various kinases

## Key Observations

1. **Picomolar potency** is rare but achievable - several compounds achieve IC50/Ki values in the 0.1-10 pM range
2. **Clinical relevance**: Many sub-nanomolar compounds are FDA-approved drugs (Ponatinib, Methotrexate, Imatinib, Paclitaxel)
3. **Target classes**: GPCRs (D2 receptor), enzymes (DHFR, AChE, Renin, Aminopeptidases), and kinases show the highest potencies
4. **Measurement variability**: The same compound can show different potencies across assays due to assay conditions

These ultra-potent compounds represent some of the most selective and efficacious drugs in pharmaceutical development, with many serving as critical therapeutics for cancer, neurological disorders, and cardiovascular disease.",,178.73736095428467,65,6959,17377,564251,"mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule, mcp__togomcp__search_chembl_molecule","[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX cco: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?molecule ?molecule_name ?target ?target_name ?activity_value ?activity_units ?activity_type\nWHERE {\n  ?activity a chembl:Activity ;\n            chembl:hasMolecule ?molecule ;\n            chembl:hasAssay ?assay ;\n            chembl:standardValue ?activity_value ;\n            chembl:standardUnits ?activity_units ;\n            chembl:type ?activity_type .\n  \n  ?assay chembl:hasTarget ?target .\n  \n  ?target a chembl:SingleProtein ;\n          chembl:organism <http://identifiers.org/taxonomy/9606> ;\n          chembl:prefLabel ?target_name .\n  \n  ?molecule chembl:prefLabel ?molecule_name .\n  \n  FILTER(?activity_type IN (\""IC50\"", \""EC50\"", \""Kd\"", \""Ki\""))\n  FILTER(?activity_units = \""nM\"")\n  FILTER(?activity_value < 1.0)\n  FILTER(?activity_value > 0)\n}\nORDER BY ?activity_value\nLIMIT 100\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT DISTINCT ?molecule ?target ?activity_value ?activity_type\nWHERE {\n  ?activity a chembl:Activity ;\n            chembl:hasMolecule ?molecule ;\n            chembl:hasAssay ?assay ;\n            chembl:standardValue ?activity_value ;\n            chembl:standardUnits \""nM\"" ;\n            chembl:type ?activity_type .\n  \n  ?assay chembl:hasTarget ?target .\n  \n  ?target chembl:organism <http://identifiers.org/taxonomy/9606> .\n  \n  FILTER(?activity_type IN (\""IC50\"", \""EC50\"", \""Kd\"", \""Ki\""))\n  FILTER(?activity_value < 1.0)\n  FILTER(?activity_value > 0)\n}\nLIMIT 50\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT ?activity_type (COUNT(*) as ?count)\nWHERE {\n  ?activity a chembl:Activity ;\n            chembl:standardUnits \""nM\"" ;\n            chembl:standardValue ?value ;\n            chembl:type ?activity_type .\n  FILTER(?value < 1.0 && ?value > 0)\n}\nGROUP BY ?activity_type\nLIMIT 20\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?molecule_id ?molecule_name ?target_id ?target_name ?activity_value ?activity_type\nWHERE {\n  ?activity a chembl:Activity ;\n            chembl:hasMolecule ?molecule ;\n            chembl:hasAssay ?assay ;\n            chembl:standardUnits \""nM\"" ;\n            chembl:standardValue ?activity_value ;\n            chembl:type ?activity_type .\n  \n  ?molecule a chembl:SmallMolecule ;\n            rdfs:label ?molecule_id ;\n            chembl:prefLabel ?molecule_name .\n  \n  ?assay chembl:hasTarget ?target .\n  \n  ?target a chembl:SingleProtein ;\n          chembl:organism <http://identifiers.org/taxonomy/9606> ;\n          rdfs:label ?target_id ;\n          chembl:prefLabel ?target_name .\n  \n  FILTER(?activity_type IN (\""Ki\"", \""IC50\"", \""EC50\"", \""Kd\""))\n  FILTER(?activity_value < 1.0 && ?activity_value > 0)\n}\nORDER BY ?activity_value\nLIMIT 30\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\n\nSELECT ?molecule ?target ?value ?type\nWHERE {\n  ?activity a chembl:Activity ;\n            chembl:hasMolecule ?molecule ;\n            chembl:hasAssay ?assay ;\n            chembl:standardValue ?value ;\n            chembl:standardUnits \""nM\"" ;\n            chembl:type ?type .\n  \n  ?assay chembl:hasTarget ?target .\n  \n  FILTER(?type = \""Ki\"")\n  FILTER(?value < 1.0 && ?value > 0)\n}\nLIMIT 30\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?molecule_id ?molecule_name ?target_id ?target_name ?organism ?value ?type\nWHERE {\n  ?activity a chembl:Activity ;\n            chembl:hasMolecule ?molecule ;\n            chembl:hasAssay ?assay ;\n            chembl:standardValue ?value ;\n            chembl:standardUnits \""nM\"" ;\n            chembl:type ?type .\n  \n  ?molecule rdfs:label ?molecule_id .\n  OPTIONAL { ?molecule chembl:prefLabel ?molecule_name }\n  \n  ?assay chembl:hasTarget ?target .\n  \n  ?target rdfs:label ?target_id .\n  OPTIONAL { ?target chembl:prefLabel ?target_name }\n  OPTIONAL { ?target chembl:organism ?org . ?org rdfs:label ?organism }\n  \n  FILTER(?type = \""Ki\"")\n  FILTER(?value < 1.0 && ?value > 0)\n}\nORDER BY ?value\nLIMIT 50\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?molecule_id ?molecule_name ?target_id ?target_name ?value ?type\nWHERE {\n  ?activity a chembl:Activity ;\n            chembl:hasMolecule ?molecule ;\n            chembl:hasAssay ?assay ;\n            chembl:standardValue ?value ;\n            chembl:standardUnits \""nM\"" ;\n            chembl:type ?type .\n  \n  ?molecule rdfs:label ?molecule_id .\n  OPTIONAL { ?molecule chembl:prefLabel ?molecule_name }\n  \n  ?assay chembl:hasTarget ?target .\n  \n  ?target a chembl:SingleProtein ;\n          chembl:organism <http://identifiers.org/taxonomy/9606> ;\n          rdfs:label ?target_id .\n  OPTIONAL { ?target chembl:prefLabel ?target_name }\n  \n  FILTER(?type IN (\""Ki\"", \""IC50\"", \""EC50\"", \""Kd\""))\n  FILTER(?value < 1.0 && ?value > 0)\n}\nORDER BY ?value\nLIMIT 100\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?target_id ?target_name ?organism_label ?target_type\nWHERE {\n  VALUES ?target { \n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL220>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL256>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL318>\n  }\n  \n  ?target rdfs:label ?target_id ;\n          a ?target_type .\n  \n  OPTIONAL { ?target chembl:prefLabel ?target_name }\n  OPTIONAL { \n    ?target chembl:organism ?organism . \n    ?organism rdfs:label ?organism_label \n  }\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?molecule_id ?molecule_name ?target_id ?target_name ?uniprot ?value ?type\nWHERE {\n  ?activity a chembl:Activity ;\n            chembl:hasMolecule ?molecule ;\n            chembl:hasAssay ?assay ;\n            chembl:standardValue ?value ;\n            chembl:standardUnits \""nM\"" ;\n            chembl:type ?type .\n  \n  ?molecule rdfs:label ?molecule_id .\n  OPTIONAL { ?molecule chembl:prefLabel ?molecule_name }\n  \n  ?assay chembl:hasTarget ?target .\n  \n  ?target a chembl:SingleProtein ;\n          rdfs:label ?target_id ;\n          chembl:hasTargetComponent ?component .\n  \n  ?component chembl:targetCmptXref ?xref .\n  ?xref a chembl:UniprotRef ;\n        chembl:xrefId ?uniprot .\n  \n  OPTIONAL { ?target chembl:prefLabel ?target_name }\n  \n  FILTER(?type IN (\""Ki\"", \""IC50\"", \""Kd\""))\n  FILTER(?value < 1.0 && ?value > 0)\n}\nORDER BY ?value\nLIMIT 50\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?molecule_id ?molecule_name ?target_id ?target_name ?value ?type\nWHERE {\n  ?activity a chembl:Activity ;\n            chembl:hasMolecule ?molecule ;\n            chembl:hasAssay ?assay ;\n            chembl:standardValue ?value ;\n            chembl:standardUnits \""nM\"" ;\n            chembl:type ?type .\n  \n  ?molecule rdfs:label ?molecule_id .\n  OPTIONAL { ?molecule chembl:prefLabel ?molecule_name }\n  \n  ?assay chembl:hasTarget ?target .\n  \n  ?target a chembl:SingleProtein ;\n          rdfs:label ?target_id .\n  OPTIONAL { ?target chembl:prefLabel ?target_name }\n  \n  FILTER(?type IN (\""IC50\"", \""Ki\"", \""Kd\""))\n  FILTER(?value < 1.0 && ?value > 0)\n}\nORDER BY ?value\nLIMIT 60\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?molecule_id ?target_id ?value ?type\nWHERE {\n  ?activity a chembl:Activity ;\n            chembl:hasMolecule ?molecule ;\n            chembl:hasAssay ?assay ;\n            chembl:standardValue ?value ;\n            chembl:standardUnits \""nM\"" ;\n            chembl:type ?type .\n  \n  ?molecule rdfs:label ?molecule_id .\n  ?assay chembl:hasTarget ?target .\n  ?target rdfs:label ?target_id .\n  \n  FILTER(?type = \""IC50\"")\n  FILTER(?value < 1.0 && ?value > 0)\n}\nORDER BY ?value\nLIMIT 40\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?molecule_id ?molecule_name ?smiles ?target_name ?value ?type\nWHERE {\n  VALUES ?molecule_id { \""PONATINIB\"" \""DITEKIREN\"" \""SPIPERONE\"" \""METHOTREXATE\"" \""IMATINIB\"" \""PACLITAXEL\"" \""DOPAMINE\"" }\n  \n  ?molecule rdfs:label ?molecule_id .\n  OPTIONAL { ?molecule chembl:prefLabel ?molecule_name }\n  OPTIONAL { ?molecule chembl:smiles ?smiles }\n  \n  ?activity chembl:hasMolecule ?molecule ;\n            chembl:hasAssay ?assay ;\n            chembl:standardValue ?value ;\n            chembl:standardUnits \""nM\"" ;\n            chembl:type ?type .\n  \n  ?assay chembl:hasTarget ?target .\n  OPTIONAL { ?target chembl:prefLabel ?target_name }\n  \n  FILTER(?type IN (\""IC50\"", \""Ki\"", \""Kd\""))\n  FILTER(?value < 1.0 && ?value > 0)\n}\nORDER BY ?molecule_id ?value\n""}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""Renin human"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""Dopamine D2 receptor human"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""Acetylcholinesterase human"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""Dihydrofolate reductase human"", ""limit"": 5}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?molecule_id ?target_name ?value ?units ?type\nWHERE {\n  VALUES ?target { \n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL286>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL217>\n    <http://rdf.ebi.ac.uk/resource/chembl/target/CHEMBL220>\n  }\n  \n  ?activity a chembl:Activity ;\n            chembl:hasMolecule ?molecule ;\n            chembl:hasAssay ?assay ;\n            chembl:standardValue ?value ;\n            chembl:standardUnits ?units ;\n            chembl:type ?type .\n  \n  ?molecule rdfs:label ?molecule_id .\n  ?assay chembl:hasTarget ?target .\n  ?target chembl:prefLabel ?target_name .\n  \n  FILTER(?type IN (\""IC50\"", \""Ki\"", \""Kd\""))\n  FILTER(?units = \""nM\"")\n  FILTER(?value < 1.0 && ?value > 0)\n}\nORDER BY ?target_name ?value\nLIMIT 100\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""\nPREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?target ?target_name (COUNT(DISTINCT ?molecule) as ?count)\nWHERE {\n  ?activity a chembl:Activity ;\n            chembl:hasMolecule ?molecule ;\n            chembl:hasAssay ?assay ;\n            chembl:standardValue ?value ;\n            chembl:standardUnits \""nM\"" ;\n            chembl:type ?type .\n  \n  ?assay chembl:hasTarget ?target .\n  ?target a chembl:SingleProtein .\n  OPTIONAL { ?target chembl:prefLabel ?target_name }\n  \n  FILTER(?type IN (\""IC50\"", \""Ki\""))\n  FILTER(?value < 1.0 && ?value > 0)\n}\nGROUP BY ?target ?target_name\nORDER BY DESC(?count)\nLIMIT 30\n""}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""Ponatinib"", ""limit"": 3}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""Ditekiren"", ""limit"": 3}}, {""name"": ""mcp__togomcp__search_chembl_molecule"", ""input"": {""query"": ""Spiperone"", ""limit"": 3}}]",CRITICAL,"Ultra-potent compounds such as RITTERAZINE B (pChembl 14.92), CEPHALOSTATIN 1 (14.82), and other natural product cytotoxins","COMPLEX QUERY requiring pChembl knowledge.

Databases/Resources: ChEMBL

Knowledge Required:
- pChembl normalized potency value (pChembl = -log10 of molar IC50/EC50/Ki)
- pChembl > 9 means sub-nanomolar potency
- xsd:decimal conversion for numeric comparison
- Human target filtering

Without proper knowledge: Cannot interpret pChembl values or filter correctly.

Verified in chembl_exploration.md Pattern 6 (pChembl Normalized Potency Search)."
50,2026-02-01,Structured Query,What biochemical reactions involve both glucose and phosphate?,True,True,False,0.3,"Many important biochemical reactions involve both glucose and phosphate. Here are the key ones:

## Glycolysis
1. **Glucose phosphorylation** - The first step of glycolysis where glucose is converted to glucose-6-phosphate (G6P) by hexokinase (or glucokinase in liver), using ATP
2. **Fructose-6-phosphate to fructose-1,6-bisphosphate** - Phosphofructokinase adds a second phosphate group
3. **Formation of glyceraldehyde-3-phosphate and dihydroxyacetone phosphate** - The 6-carbon sugar splits into two 3-carbon phosphorylated molecules

## Gluconeogenesis
- The reverse pathway that synthesizes glucose from non-carbohydrate precursors, involving multiple phosphorylated intermediates
- **Glucose-6-phosphatase** removes phosphate from G6P to produce free glucose (final step)

## Glycogen Metabolism
- **Glycogen phosphorylase** breaks down glycogen using inorganic phosphate to produce glucose-1-phosphate
- **Phosphoglucomutase** interconverts glucose-1-phosphate and glucose-6-phosphate

## Pentose Phosphate Pathway
- Glucose-6-phosphate enters this pathway for NADPH production and synthesis of ribose-5-phosphate

## Other Key Reactions
- **Substrate-level phosphorylation** in glycolysis where phosphate groups from intermediates are transferred to ADP to form ATP
- Various **phosphorylation/dephosphorylation** reactions regulating glucose metabolism enzymes

These phosphate groups are crucial for trapping glucose in cells, providing energy coupling, and regulating metabolic pathways.",,8.856399774551392,48,414,True,True,0.5,"Great! I found many biochemical reactions involving glucose and phosphate. Let me organize these into key categories:

## Biochemical Reactions Involving Glucose and Phosphate

Here are the major types of reactions:

### 1. **Glucose Phosphorylation (Adding Phosphate to Glucose)**
- **RHEA:17825**: `D-glucose + ATP = D-glucose 6-phosphate + ADP + H⁺`
  - This is the classic **hexokinase/glucokinase reaction** - the first step of glycolysis
- **RHEA:36495**: `α-D-glucose + ATP = α-D-glucose 6-phosphate + ADP + H⁺`
  - Alternative form specifying the α-anomer

### 2. **Dephosphorylation (Removing Phosphate from Glucose)**
- **RHEA:16689**: `D-glucose 6-phosphate + H₂O = D-glucose + phosphate`
  - Catalyzed by **glucose-6-phosphatase** - important in gluconeogenesis
- **RHEA:19933**: `α-D-glucose 1-phosphate + H₂O = D-glucose + phosphate`
  - Removes phosphate from position 1

### 3. **Phosphorolysis (Using Inorganic Phosphate to Break Bonds)**
- **RHEA:16257**: `α,α-trehalose + phosphate = α-D-glucose + α-D-glucose 1-phosphate`
  - Trehalose breakdown
- **RHEA:19493**: `D-cellobiose + phosphate = α-D-glucose 1-phosphate + D-glucose`
  - Cellobiose breakdown
- **RHEA:21116**: `D-maltose + phosphate = β-D-glucose 1-phosphate + D-glucose`
  - Maltose breakdown

### 4. **Glucose-Phosphate Isomerization**
- **RHEA:11816**: `α-D-glucose 6-phosphate = β-D-fructose 6-phosphate`
  - **Phosphoglucose isomerase** - second step of glycolysis
- **RHEA:16249**: `α-D-glucose 6-phosphate = β-D-glucose 6-phosphate`
  - Interconversion of anomers

### 5. **Nucleotide-Sugar Formation**
- **RHEA:19889**: `α-D-glucose 1-phosphate + UTP + H⁺ = UDP-α-D-glucose + diphosphate`
  - Forms UDP-glucose for glycogen synthesis
- **RHEA:12120**: `α-D-glucose 1-phosphate + ATP + H⁺ = ADP-α-D-glucose + diphosphate`
  - Forms ADP-glucose for starch synthesis

### 6. **Glucose-6-Phosphate Dehydrogenase Reactions**
- **RHEA:15841**: `D-glucose 6-phosphate + NADP⁺ = 6-phospho-D-glucono-1,5-lactone + NADPH + H⁺`
  - First step of the **pentose phosphate pathway**

### 7. **Transport Reactions**
- **RHEA:60184**: `D-glucose(out) + ATP + H₂O = D-glucose(in) + ADP + phosphate + H⁺`
  - ATP-dependent glucose transport

These reactions are fundamental to metabolism, including **glycolysis**, **gluconeogenesis**, **glycogen/starch metabolism**, **pentose phosphate pathway**, and **carbohydrate transport**.",,23.951815843582153,9,1010,29778,26295,mcp__togomcp__search_rhea_entity,"[{""name"": ""mcp__togomcp__search_rhea_entity"", ""input"": {""query"": ""glucose phosphate"", ""limit"": 50}}]",CRITICAL,"Reactions such as RHEA:16689 (D-glucose 6-phosphate hydrolysis), RHEA:19933 (alpha-D-glucose 1-phosphate hydrolysis)","COMPLEX QUERY requiring boolean text search knowledge.

Databases/Resources: Rhea

Knowledge Required:
- bif:contains with boolean operators ('glucose' AND 'phosphate')
- Proper quoting syntax for keywords
- Score option for relevance ranking
- rhea:status rhea:Approved filter

Without proper knowledge: Cannot construct boolean search correctly.

Verified in rhea_exploration.md Pattern 6 (Boolean Text Search)."
51,2026-02-01,Integration,How many genes are annotated with the autophagy Gene Ontology term?,True,False,True,1.0,"I don't have access to current database statistics for the exact number of genes annotated with autophagy Gene Ontology (GO) terms. The number varies depending on:

1. **Which specific GO term** you're referring to:
   - ""autophagy"" (GO:0006914) - the general term
   - More specific terms like ""macroautophagy"" (GO:0016236), ""microautophagy"" (GO:0016237), ""chaperone-mediated autophagy"" (GO:0061684), etc.

2. **Which organism** you're interested in (human, mouse, yeast, etc.)

3. **Evidence codes** - whether you include all annotations or only experimentally validated ones

4. **When the data was accessed** - GO annotations are continuously updated

As a general reference, the core autophagy machinery in humans involves around 40-50 well-characterized ATG (autophagy-related) genes, but when you include regulators, cargo receptors, and genes in related processes, hundreds to thousands of genes may be annotated with autophagy-related GO terms.

To get the current exact number, you would need to query the Gene Ontology database (geneontology.org) or use tools like AmiGO, QuickGO, or organism-specific databases.",,8.299442768096924,54,301,True,True,1.0,"Perfect! Now I have comprehensive information about autophagy gene annotations. Let me provide you with the answer:

## Gene Annotations with the Autophagy GO Term

Based on queries to the UniProt database, here are the gene annotation counts for the autophagy Gene Ontology term (**GO:0006914**):

### Overall Results:
- **79,227 proteins** across all organisms are directly annotated with the autophagy term (GO:0006914)

### Human-Specific Results:
- **332 human proteins** (from *Homo sapiens*, taxonomy ID 9606) are annotated with the autophagy term

### Important Notes:
1. These counts represent **direct annotations** to the autophagy term (GO:0006914), which is defined as: *""The cellular catabolic process in which cells digest cellular materials, such as organelles and other macromolecular constituents, or non-self materials such as intracellular pathogens.""*

2. The Gene Ontology has **72 total terms** related to autophagy, including more specific child terms like:
   - Autophagy of mitochondrion (GO:0000422)
   - Autophagy of peroxisome (GO:0030242)
   - Chaperone-mediated autophagy (GO:0061684)
   - And many regulatory terms

3. If you include all genes annotated with autophagy-related child terms, the total number would be higher, but my query for that comprehensive count timed out due to the computational complexity.",,44.954193115234375,29,1386,15937,217064,"mcp__ols__searchClasses, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""autophagy"", ""ontologyId"": ""go""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT (COUNT(DISTINCT ?protein) AS ?count)\nWHERE {\n  ?protein a up:Protein ;\n           up:annotation ?annotation .\n  ?annotation a up:Function_Annotation ;\n              up:classifiedWith <http://purl.obolibrary.org/obo/GO_0006914> .\n}""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT (COUNT(DISTINCT ?protein) AS ?count)\nWHERE {\n  ?protein a up:Protein ;\n           up:classifiedWith <http://purl.obolibrary.org/obo/GO_0006914> .\n}""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT (COUNT(DISTINCT ?protein) AS ?count)\nWHERE {\n  ?protein a up:Protein ;\n           up:classifiedWith ?go .\n  ?go rdfs:subClassOf* <http://purl.obolibrary.org/obo/GO_0006914> .\n}""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\n\nSELECT (COUNT(DISTINCT ?protein) AS ?count)\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:classifiedWith <http://purl.obolibrary.org/obo/GO_0006914> .\n}""}}]",CRITICAL,"29,615 genes annotated with autophagy (GO:0006914)","COMPLEX QUERY requiring TogoID integration knowledge.

Databases/Resources: GO, NCBI Gene (via TogoID)

Knowledge Required:
- TogoID relation graph: http://rdfportal.org/dataset/togoid/relation/ncbigene-go
- togoid:TIO_000004 property for gene-GO links
- GO term URI format
- Pre-computed mappings enable fast queries

Without proper knowledge: Cannot access TogoID relation graphs for gene annotations.

Verified in go_exploration.md Pattern 5 (TogoID Integration for Gene Annotations)."
52,2026-02-01,Integration,What are the GO annotations for the human TP53 gene?,True,True,True,0.5555555555555556,"# GO Annotations for Human TP53 Gene

TP53 (tumor protein p53) has extensive Gene Ontology annotations across all three GO domains. Here are the major ones:

## Molecular Function (MF)
- **DNA-binding transcription factor activity**
- **Sequence-specific DNA binding**
- **Protein binding** (interacts with numerous proteins)
- **Zinc ion binding**
- **Chromatin binding**
- **Transcription coactivator/corepressor activity**
- **Protein homodimerization activity**
- **Ubiquitin protein ligase binding**

## Biological Process (BP)
- **Regulation of transcription** (DNA-templated)
- **Apoptotic process/programmed cell death**
- **Cell cycle arrest** (particularly G1/S and G2/M checkpoints)
- **DNA damage response**
- **Cellular senescence**
- **Negative regulation of cell proliferation**
- **Response to stress**
- **Regulation of autophagy**
- **Intrinsic apoptotic signaling pathway**
- **Mitochondrial fragmentation**
- **Replicative senescence**

## Cellular Component (CC)
- **Nucleus**
- **Nucleoplasm**
- **Cytoplasm**
- **Mitochondrion**
- **PML body** (promyelocytic leukemia nuclear bodies)
- **Transcription factor complex**
- **Chromatin**

TP53 is one of the most well-studied genes, functioning primarily as a tumor suppressor and ""guardian of the genome"" by regulating cell cycle, apoptosis, and DNA repair in response to cellular stress.",,8.195096015930176,51,400,True,False,0.4444444444444444,"Perfect! I've retrieved extensive GO annotations for the human TP53 gene. Let me organize these by the three main GO categories (Molecular Function, Biological Process, and Cellular Component).

## GO Annotations for Human TP53 Gene (UniProt: P04637)

The human TP53 gene encodes the tumor protein p53, one of the most important tumor suppressors. Here are its GO annotations organized by category:

### **Molecular Function (MF)** - What the protein does:

**DNA Binding & Transcription:**
- DNA binding (GO:0003677)
- DNA-binding transcription factor activity (GO:0003700)
- DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981)
- DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228)
- DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227)
- Chromatin binding (GO:0003682)
- Core promoter sequence-specific DNA binding (GO:0001046)
- Transcription cis-regulatory region binding (GO:0000976)
- RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978)

**Protein Binding:**
- Identical protein binding (GO:0042802) - forms tetramers
- p53 binding (GO:0002039)
- Enzyme binding (GO:0019899)
- Ubiquitin protein ligase binding (GO:0031625) - e.g., MDM2
- MDM2/MDM4 family protein binding (GO:0097371)
- Histone deacetylase binding (GO:0042826)
- Protein heterodimerization activity (GO:0046982)

**Other Activities:**
- Zinc ion binding (GO:0008270)
- Copper ion binding (GO:0005507)
- Protein tetramerization (GO:0051262)
- ATP-dependent DNA/DNA annealing activity (GO:0036310)

### **Biological Process (BP)** - What processes the protein is involved in:

**DNA Damage Response & Cell Cycle:**
- DNA damage response (GO:0006974)
- DNA damage response, signal transduction by p53 class mediator (GO:0030330)
- DNA damage response resulting in cell cycle arrest (GO:0006977)
- Signal transduction by p53 class mediator (GO:0072331)
- Regulation of cell cycle (GO:0051726)
- Mitotic G1 DNA damage checkpoint signaling (GO:0031571)

**Apoptosis & Cell Death:**
- Positive regulation of apoptotic process (GO:0043065)
- Intrinsic apoptotic signaling pathway by p53 class mediator (GO:0072332)
- Intrinsic apoptotic signaling pathway in response to DNA damage (GO:0042771)
- Positive regulation of neuron apoptotic process (GO:0043525)
- Necroptotic process (GO:0070266)

**Transcription Regulation:**
- Positive regulation of transcription by RNA polymerase II (GO:0045944)
- Negative regulation of transcription by RNA polymerase II (GO:0000122)
- Regulation of DNA-templated transcription (GO:0006355)
- Positive regulation of gene expression (GO:0010628)

**Cell Proliferation & Senescence:**
- Negative regulation of cell population proliferation (GO:0008285)
- Cellular senescence (GO:0090398)
- Replicative senescence (GO:0090399)
- Positive regulation of cellular senescence (GO:2000774)

**Metabolism & Stress Response:**
- Negative regulation of glucose catabolic process to lactate (GO:1904024)
- Response to ionizing radiation (GO:0071479)
- Cellular response to hypoxia (GO:0071456)
- Cellular response to UV (GO:0034644)
- Reactive oxygen species metabolic process (GO:0072593)

**DNA Repair:**
- Nucleotide-excision repair (GO:0006289)
- Double-strand break repair (GO:0006302)
- Mitochondrial DNA repair (GO:0043504)

**Development & Differentiation:**
- In utero embryonic development (GO:0001701)
- Hematopoietic progenitor cell differentiation (GO:0002244)
- T cell differentiation in thymus (GO:0033077)
- Embryonic organ development (GO:0048568)

### **Cellular Component (CC)** - Where the protein is located:

**Nuclear Locations:**
- Nucleus (GO:0005634)
- Nucleoplasm (GO:0005654)
- Nucleolus (GO:0005730)
- Chromatin (GO:0000785)
- Nuclear matrix (GO:0016363)
- PML body (GO:0016605)
- Transcription factor complex (GO:0005667)

**Cytoplasmic Locations:**
- Cytoplasm (GO:0005737)
- Cytosol (GO:0005829)
- Mitochondrion (GO:0005739)
- Mitochondrial matrix (GO:0005759)
- Endoplasmic reticulum (GO:0005783)
- Centrosome (GO:0005813)

### Summary:

TP53 has **extensive GO annotations** reflecting its critical role as a tumor suppressor. Key functions include:
- **Transcription factor** regulating hundreds of target genes
- **DNA damage sensor** triggering cell cycle arrest or apoptosis
- **Guardian of the genome** preventing cancer development
- **Regulator of metabolism, senescence, and autophagy**

The protein is primarily nuclear but can also localize to mitochondria and cytoplasm under certain stress conditions.",,62.88045907020569,30,2791,9343,166092,"mcp__togomcp__search_uniprot_entity, mcp__togomcp__ncbi_esearch, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__search_uniprot_entity"", ""input"": {""query"": ""TP53 human"", ""limit"": 5}}, {""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""gene"", ""query"": ""TP53 AND human[organism]"", ""max_results"": 1}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?goTerm ?goLabel ?goCategory ?evidence\nWHERE {\n  <http://purl.uniprot.org/uniprot/P04637> a up:Protein ;\n    up:classifiedWith ?goTerm .\n  \n  ?goTerm rdfs:label ?goLabel ;\n    up:category ?goCategory .\n  \n  OPTIONAL {\n    <http://purl.uniprot.org/uniprot/P04637> up:annotation ?annotation .\n    ?annotation a up:Function_Annotation ;\n      up:classifiedWith ?goTerm ;\n      up:evidence ?evidenceNode .\n    ?evidenceNode rdfs:label ?evidence .\n  }\n}\nORDER BY ?goCategory ?goLabel""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\n\nSELECT DISTINCT ?goTerm ?goLabel ?aspect\nWHERE {\n  <http://purl.uniprot.org/uniprot/P04637> up:classifiedWith ?goTerm .\n  ?goTerm a up:Concept .\n  ?goTerm rdfs:label ?goLabel .\n  \n  OPTIONAL { ?goTerm up:category ?aspect }\n}\nORDER BY ?aspect ?goLabel\nLIMIT 100""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?goId ?goLabel\nWHERE {\n  <http://purl.uniprot.org/uniprot/P04637> up:classifiedWith ?go .\n  ?go rdfs:label ?goLabel .\n  BIND(REPLACE(STR(?go), \""http://purl.obolibrary.org/obo/GO_\"", \""GO:\"") AS ?goId)\n  FILTER(CONTAINS(STR(?go), \""obolibrary\""))\n}\nORDER BY ?goId\nLIMIT 200""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""PREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?goId ?goLabel\nWHERE {\n  <http://purl.uniprot.org/uniprot/P04637> up:classifiedWith ?go .\n  ?go rdfs:label ?goLabel .\n  BIND(REPLACE(STR(?go), \""http://purl.obolibrary.org/obo/GO_\"", \""GO:\"") AS ?goId)\n  FILTER(CONTAINS(STR(?go), \""obolibrary\""))\n}\nORDER BY ?goId\nLIMIT 200\nOFFSET 200""}}]",VALUABLE,"GO terms associated with TP53/p53 including DNA binding, transcription regulation, apoptosis","SIMPLE QUERY - Straightforward GO annotation lookup.

Method: togoid_convertId with gene ID 7157 to GO

Demonstrates when basic ID conversion and mapping tools suffice.

Verified in go_exploration.md simple queries section."
53,2026-02-01,Completeness,What fraction of Rhea reactions have Gene Ontology molecular function annotations?,True,False,True,0.5,"I don't have specific statistics about what fraction of Rhea reactions have Gene Ontology (GO) molecular function annotations in my training data.

However, I can provide some context:

Rhea is a comprehensive database of biochemical reactions that is expert-curated and uses ChEBI (Chemical Entities of Biological Interest) for chemical structures. Rhea reactions are cross-referenced with various databases including:

1. **EC (Enzyme Commission) numbers** - which classify enzymatic reactions
2. **UniProt** - protein sequence database
3. **Gene Ontology** - including molecular function terms

The connection between Rhea and GO molecular function annotations typically occurs through:
- Reactions that are catalyzed by enzymes with known GO molecular function terms
- Cross-references via EC numbers and UniProt entries

Not all Rhea reactions would necessarily have GO molecular function annotations because:
- Some reactions may be non-enzymatic (spontaneous)
- Some enzymatic reactions may not yet have characterized enzymes
- The annotation process is ongoing

To get the exact fraction, you would need to query the current Rhea database directly or check their latest statistics documentation, as this number changes as both databases are continuously updated and curated.",,8.515293836593628,53,272,True,True,0.75,"Perfect! The only property linking Rhea reactions to GO terms is `rdfs:seeAlso`, and it accounts for exactly 4,443 reactions.

## Answer

Based on my analysis of the Rhea and Gene Ontology databases:

**Approximately 6.7% (4,443 out of 66,740) of Rhea reactions have Gene Ontology molecular function annotations.**

### Details:
- **Total approved Rhea reactions**: 66,740
- **Reactions with GO molecular function annotations**: 4,443
- **Fraction**: 4,443 / 66,740 = **0.0666 or ~6.66%**

These GO annotations are linked to Rhea reactions via the `rdfs:seeAlso` property in the Rhea RDF database. The GO terms represent specific enzymatic activities (molecular functions) such as hydrolase activity, transferase activity, and other catalytic functions that correspond to the biochemical reactions in Rhea.

For context, 7,432 Rhea reactions (11.1%) have EC number annotations, which is higher than the GO molecular function coverage. This suggests that while many enzymatic reactions are classified by EC numbers, a smaller subset has been explicitly linked to GO molecular function terms.",,194.5362000465393,103,5629,13104,703830,"mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, WebSearch, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__ols__fetch, mcp__ols__fetch, mcp__ols__fetch, mcp__ols__getAncestors, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?total_reactions)\nWHERE {\n  ?reaction a rh:Reaction .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX up: <http://purl.uniprot.org/core/>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?reactions_with_go_mf)\nWHERE {\n  ?reaction a rh:Reaction .\n  ?reaction rdfs:subClassOf ?restriction .\n  ?restriction a <http://www.w3.org/2002/07/owl#Restriction> ;\n               <http://www.w3.org/2002/07/owl#onProperty> up:catalyzedBy ;\n               <http://www.w3.org/2002/07/owl#someValuesFrom> ?goMF .\n  FILTER(STRSTARTS(STR(?goMF), \""http://purl.obolibrary.org/obo/GO_\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT ?type (COUNT(*) AS ?count)\nWHERE {\n  ?s a ?type .\n}\nGROUP BY ?type\nLIMIT 20\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nSELECT (COUNT(*) AS ?total)\nWHERE {\n  ?s ?p ?o .\n}\nLIMIT 1\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""sib"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX up: <http://purl.uniprot.org/core/>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?total_reactions)\nWHERE {\n  ?reaction rh:status rh:Approved .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""sib"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX up: <http://purl.uniprot.org/core/>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?reactions_with_go)\nWHERE {\n  ?reaction rh:status rh:Approved .\n  ?reaction rdfs:subClassOf ?class .\n  FILTER(STRSTARTS(STR(?class), \""http://purl.obolibrary.org/obo/GO_\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""sib"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX owl: <http://www.w3.org/2002/07/owl#>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?reactions_with_go_mf)\nWHERE {\n  ?reaction rh:status rh:Approved .\n  ?reaction rdfs:subClassOf ?restriction .\n  ?restriction owl:onProperty up:catalyzedBy ;\n               owl:someValuesFrom ?goClass .\n  FILTER(REGEX(STR(?goClass), \""GO_\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""sib"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT ?p (COUNT(*) AS ?count)\nWHERE {\n  ?reaction rh:status rh:Approved .\n  ?reaction ?p ?o .\n}\nGROUP BY ?p\nORDER BY DESC(?count)\nLIMIT 20\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""sib"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?subClass\nWHERE {\n  ?reaction rh:status rh:Approved .\n  ?reaction rdfs:subClassOf ?subClass .\n  FILTER(REGEX(STR(?subClass), \""GO_\""))\n}\nLIMIT 10\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""sib"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?subClass\nWHERE {\n  ?reaction rh:status rh:Approved .\n  ?reaction rdfs:subClassOf ?subClass .\n}\nLIMIT 20\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""sib"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?reactions_with_uniprot)\nWHERE {\n  ?reaction rh:status rh:Approved .\n  ?protein up:annotation ?annotation .\n  ?annotation up:catalyticActivity ?activity .\n  ?activity up:catalyzedReaction ?reaction .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""sib"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT ?o\nWHERE {\n  ?s ?p ?o .\n  FILTER(REGEX(STR(?o), \""purl.obolibrary.org/obo/GO\""))\n}\nLIMIT 10\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT (COUNT(DISTINCT ?rheaReaction) AS ?count)\nWHERE {\n  ?protein up:annotation ?annotation .\n  ?annotation a up:Catalytic_Activity_Annotation ;\n              up:catalyticActivity ?activity .\n  ?activity up:catalyzedReaction ?rheaReaction .\n  FILTER(STRSTARTS(STR(?rheaReaction), \""http://rdf.rhea-db.org/\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""sib"", ""sparql_query"": ""\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT (COUNT(DISTINCT ?rheaReaction) AS ?rhea_in_uniprot)\nWHERE {\n  ?protein up:annotation ?annotation .\n  ?annotation a up:Catalytic_Activity_Annotation ;\n              up:catalyticActivity ?activity .\n  ?activity up:catalyzedReaction ?rheaReaction .\n  FILTER(STRSTARTS(STR(?rheaReaction), \""http://rdf.rhea-db.org/\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""sib"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX obo: <http://purl.obolibrary.org/obo/>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?reactions_with_go)\nWHERE {\n  ?reaction rh:status rh:Approved .\n  ?s ?p ?reaction .\n  ?s ?p2 ?go .\n  FILTER(STRSTARTS(STR(?go), \""http://purl.obolibrary.org/obo/GO_\""))\n}\nLIMIT 1\n""}}, {""name"": ""WebSearch"", ""input"": {""query"": ""Rhea reactions Gene Ontology molecular function annotations coverage fraction 2025""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""sib"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?reactions_with_ec)\nWHERE {\n  ?reaction rh:status rh:Approved ;\n            rh:ec ?ec .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""primary"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX oboInOwl: <http://www.geneontology.org/formats/oboInOwl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?count)\nWHERE {\n  SERVICE <https://sparql.rhea-db.org/sparql> {\n    ?reaction rh:status rh:Approved .\n  }\n  SERVICE <https://sparql.hegroup.org/sparql> {\n    ?goterm rdfs:label ?label .\n    FILTER(STRSTARTS(STR(?goterm), \""http://purl.obolibrary.org/obo/GO_\""))\n  }\n}\nLIMIT 1\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""sib"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?seeAlso\nWHERE {\n  ?reaction rh:status rh:Approved ;\n            rdfs:seeAlso ?seeAlso .\n}\nLIMIT 20\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""sib"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT (COUNT(DISTINCT ?reaction) AS ?reactions_with_go)\nWHERE {\n  ?reaction rh:status rh:Approved ;\n            rdfs:seeAlso ?go .\n  FILTER(STRSTARTS(STR(?go), \""http://purl.obolibrary.org/obo/GO_\""))\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""sib"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?go\nWHERE {\n  ?reaction rh:status rh:Approved ;\n            rdfs:seeAlso ?go .\n  FILTER(STRSTARTS(STR(?go), \""http://purl.obolibrary.org/obo/GO_\""))\n}\nLIMIT 50\n""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0047520""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0003841""}}, {""name"": ""mcp__ols__fetch"", ""input"": {""id"": ""go+http://purl.obolibrary.org/obo/GO_0004768""}}, {""name"": ""mcp__ols__getAncestors"", ""input"": {""ontologyId"": ""go"", ""classIri"": ""http://purl.obolibrary.org/obo/GO_0047520""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""endpoint_name"": ""sib"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT ?p (COUNT(DISTINCT ?reaction) AS ?count)\nWHERE {\n  ?reaction rh:status rh:Approved .\n  ?reaction ?p ?o .\n  FILTER(REGEX(STR(?o), \""purl.obolibrary.org/obo/GO\""))\n}\nGROUP BY ?p\n""}}]",CRITICAL,"Approximately 26% (4,436 reactions out of 16,685 have GO links)","COMPLEX QUERY requiring cross-reference knowledge.

Databases/Resources: Rhea

Knowledge Required:
- rdfs:seeAlso for GO cross-references
- GO URI pattern filtering (http://purl.obolibrary.org/obo/GO_)
- COUNT and ratio calculation
- rhea:status filter

Without proper knowledge: Cannot identify GO cross-references correctly.

Verified in rhea_exploration.md cross-references section."
54,2026-02-01,Completeness,How many deprecated GO terms exist in the database?,True,False,True,0.5,"I don't have access to real-time database information or the ability to query databases directly. The number of deprecated GO (Gene Ontology) terms changes over time as the ontology is continuously updated and refined.

However, I can tell you that:

1. GO terms are regularly deprecated when they become obsolete, are merged with other terms, or are found to be incorrectly defined
2. Deprecated terms are retained in the GO database with an ""obsolete"" status to maintain backward compatibility and traceability
3. The exact count would need to be queried from the current GO database

To find the current number of deprecated GO terms, you would need to:
- Query the GO database directly (available at geneontology.org)
- Use the GO API or download the GO OBO/OWL file
- Search for terms with the ""is_obsolete: true"" tag

I cannot provide you with a specific number without access to the current database.",,7.773002862930298,47,211,True,True,0.5,"Based on the search results from the Gene Ontology database in OLS, there are **8,853 deprecated (obsolete) GO terms**.

The search identified these as terms labeled with ""obsolete"" in their names. These are terms that have been removed from active use in the Gene Ontology, typically because they were:
- Redundant with other terms
- Incorrectly defined
- Representing gene products rather than biological concepts
- No longer considered useful for annotation purposes

Deprecated terms are kept in the ontology for historical reference and to maintain the integrity of older annotations, but they should not be used for new annotations.",,14.06269383430481,8,267,608,52258,mcp__ols__searchClasses,"[{""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""obsolete"", ""ontologyId"": ""go"", ""pageSize"": 1}}]",CRITICAL,"11,905 deprecated terms (approximately 25% of total)","COMPLEX QUERY requiring deprecation knowledge.

Databases/Resources: GO

Knowledge Required:
- owl:deprecated property for deprecated terms
- FROM clause for consistent results
- COUNT aggregation

Without proper knowledge: FROM clause omission causes inconsistent counts.

Verified in go_exploration.md Pattern 2."
55,2026-02-01,Specificity,Find human proteins that have both kinase activity and nuclear localization.,True,True,True,0.7777777777777778,"I can help you identify human proteins with both kinase activity and nuclear localization.

Based on my training knowledge, here are some well-characterized examples of human nuclear kinases:

## Major Nuclear Kinases:

1. **CDKs (Cyclin-Dependent Kinases)**
   - CDK1, CDK2, CDK4, CDK6, CDK7, CDK9
   - Regulate cell cycle and transcription in the nucleus

2. **Aurora Kinases**
   - Aurora A and Aurora B
   - Localize to centrosomes, spindle poles, and chromosomes during mitosis

3. **Checkpoint Kinases**
   - CHK1 and CHK2
   - DNA damage response kinases that phosphorylate nuclear substrates

4. **DNA-PK (DNA-dependent Protein Kinase)**
   - Catalytic subunit DNA-PKcs
   - Nuclear kinase involved in DNA double-strand break repair

5. **ATM (Ataxia Telangiectasia Mutated)**
   - Nuclear serine/threonine kinase
   - Master regulator of DNA damage response

6. **ATR (ATM and Rad3-related)**
   - Nuclear kinase responding to replication stress

7. **Polo-like Kinases (PLKs)**
   - PLK1 particularly has nuclear functions
   - Cell cycle regulation

8. **MAPKs (some isoforms)**
   - ERK1/2, p38, JNK can translocate to nucleus
   - Phosphorylate transcription factors

9. **NEK family (NIMA-related kinases)**
   - Several members localize to nucleus/centrosomes

Would you like more detailed information about any specific nuclear kinase family or their functions?",,9.087275981903076,51,420,True,True,0.7777777777777778,"Perfect! I found a comprehensive list of human proteins with both kinase activity and nuclear localization. Here are the results:

## Human Proteins with Both Kinase Activity and Nuclear Localization

I found **30 reviewed (SwissProt) human proteins** that have both kinase activity and nuclear localization. Here are the key examples:

### Cell Cycle Kinases
- **CDK1** (Cyclin-dependent kinase 1) - Master cell cycle regulator
- **CDK5** (Cyclin-dependent kinase 5) - Neuronal development and function
- **CDK9** (Cyclin-dependent kinase 9) - Transcription regulation
- **CDKL5** (Cyclin-dependent kinase-like 5) - Neurological development
- **CDC7** (Cell division cycle 7-related protein kinase) - DNA replication

### Signal Transduction Kinases
- **AKT1** (RAC-alpha serine/threonine-protein kinase) - PI3K/AKT pathway
- **ABL1** (Tyrosine-protein kinase ABL1) - Cell differentiation and division
- **mTOR** (Serine/threonine-protein kinase mTOR) - Cell growth and metabolism
- **GSK3B** (Glycogen synthase kinase-3 beta) - Metabolism and signaling
- **PRKD1** (Serine/threonine-protein kinase D1) - Signal transduction

### Stress Response & Immunity Kinases
- **EIF2AK2** (Interferon-induced, double-stranded RNA-activated protein kinase) - Antiviral response
- **IRAK1** (Interleukin-1 receptor-associated kinase 1) - Immune signaling
- **IRAK4** (Interleukin-1 receptor-associated kinase 4) - Innate immunity

### Other Notable Nuclear Kinases
- **CAMK2A** (Calcium/calmodulin-dependent protein kinase type II alpha) - Calcium signaling
- **CSNK2A1** (Casein kinase II subunit alpha) - Multiple cellular processes
- **SYK** (Tyrosine-protein kinase SYK) - Immune cell signaling
- **LYN** (Tyrosine-protein kinase Lyn) - Signal transduction
- **TAF1** (Transcription initiation factor TFIID subunit 1) - Has kinase activity
- **PIK3CB** (Phosphatidylinositol 4,5-bisphosphate 3-kinase) - Lipid kinase
- **VRK1** (Serine/threonine-protein kinase VRK1) - Cell cycle progression

These proteins play crucial roles in cell cycle regulation, transcription, signal transduction, DNA repair, and immune responses. Their nuclear localization allows them to directly phosphorylate nuclear substrates including transcription factors, chromatin proteins, and DNA repair proteins.",,61.10685706138611,35,2914,9237,197875,"mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__ols__search, mcp__ols__search, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\n\nSELECT DISTINCT ?protein ?proteinName ?geneName\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:annotation ?kinaseAnnotation ;\n           up:annotation ?locationAnnotation .\n  \n  # Kinase activity\n  ?kinaseAnnotation a up:Function_Annotation ;\n                    rdfs:comment ?kinaseComment .\n  FILTER(CONTAINS(LCASE(?kinaseComment), \""kinase\""))\n  \n  # Nuclear localization\n  ?locationAnnotation a up:Subcellular_Location_Annotation ;\n                      up:locatedIn ?location .\n  ?location rdfs:comment ?locationComment .\n  FILTER(CONTAINS(LCASE(?locationComment), \""nucleus\""))\n  \n  # Get protein name\n  OPTIONAL { ?protein up:recommendedName ?recName .\n             ?recName up:fullName ?proteinName . }\n  \n  # Get gene name\n  OPTIONAL { ?protein up:encodedBy ?gene .\n             ?gene skos:prefLabel ?geneName . }\n}\nLIMIT 50\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\n\nSELECT DISTINCT ?protein ?proteinName ?geneName\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:classifiedWith ?goMolecular ;\n           up:annotation ?locationAnnotation .\n  \n  # Kinase activity via GO molecular function\n  ?goMolecular rdfs:subClassOf* <http://purl.obolibrary.org/obo/GO_0016301> .\n  \n  # Nuclear localization\n  ?locationAnnotation a up:Subcellular_Location_Annotation ;\n                      up:locatedIn ?location .\n  ?location up:partOf* <http://purl.uniprot.org/locations/191> .\n  \n  # Get protein name\n  OPTIONAL { ?protein up:recommendedName ?recName .\n             ?recName up:fullName ?proteinName . }\n  \n  # Get gene name\n  OPTIONAL { ?protein up:encodedBy ?gene .\n             ?gene skos:prefLabel ?geneName . }\n}\nLIMIT 50\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\n\nSELECT DISTINCT ?protein ?proteinName ?geneName ?keyword1 ?keyword2\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:mnemonic ?mnemonic ;\n           up:classifiedWith ?keyword1 ;\n           up:classifiedWith ?keyword2 .\n  \n  ?keyword1 a up:Keyword ;\n            rdfs:label ?label1 .\n  FILTER(CONTAINS(LCASE(?label1), \""kinase\""))\n  \n  ?keyword2 a up:Keyword ;\n            rdfs:label ?label2 .\n  FILTER(CONTAINS(LCASE(?label2), \""nucleus\""))\n  \n  OPTIONAL { ?protein up:recommendedName ?recName .\n             ?recName up:fullName ?proteinName . }\n  \n  OPTIONAL { ?protein up:encodedBy ?gene .\n             ?gene skos:prefLabel ?geneName . }\n}\nLIMIT 50\n""}}, {""name"": ""mcp__ols__search"", ""input"": {""query"": ""kinase activity""}}, {""name"": ""mcp__ols__search"", ""input"": {""query"": ""nucleus""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\n\nSELECT DISTINCT ?protein ?proteinName ?geneName\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:classifiedWith <http://purl.obolibrary.org/obo/GO_0016301> ;\n           up:classifiedWith <http://purl.obolibrary.org/obo/GO_0005634> .\n  \n  OPTIONAL { ?protein up:recommendedName ?recName .\n             ?recName up:fullName ?proteinName . }\n  \n  OPTIONAL { ?protein up:encodedBy ?gene .\n             ?gene skos:prefLabel ?geneName . }\n}\nLIMIT 100\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""uniprot"", ""sparql_query"": ""\nPREFIX up: <http://purl.uniprot.org/core/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\nPREFIX taxon: <http://purl.uniprot.org/taxonomy/>\nPREFIX skos: <http://www.w3.org/2004/02/skos/core#>\n\nSELECT DISTINCT ?protein ?proteinName ?geneName\nWHERE {\n  ?protein a up:Protein ;\n           up:organism taxon:9606 ;\n           up:classifiedWith <http://purl.obolibrary.org/obo/GO_0016301> ;\n           up:classifiedWith <http://purl.obolibrary.org/obo/GO_0005634> ;\n           up:reviewed true .\n  \n  OPTIONAL { ?protein up:recommendedName ?recName .\n             ?recName up:fullName ?proteinName . }\n  \n  OPTIONAL { ?protein up:encodedBy ?gene .\n             ?gene skos:prefLabel ?geneName . }\n}\nORDER BY ?geneName\nLIMIT 200\n""}}]",VALUABLE,Human proteins with both kinase GO function and nuclear GO component annotations,"COMPLEX QUERY requiring multiple GO annotation filtering.

Databases/Resources: UniProt, GO

Knowledge Required:
- Multiple GO annotations on same protein
- up:classifiedWith for GO links
- GO URI patterns for function vs component
- Two graphs required (uniprot and go)
- up:reviewed 1 filter

Without proper knowledge: Cannot combine multiple GO criteria correctly.

Verified in uniprot_exploration.md (complex filtering patterns)."
56,2026-02-01,Specificity,What are the direct parent terms of 'macroautophagy' in Gene Ontology?,True,True,True,0.8333333333333334,"In Gene Ontology, the direct parent term of 'macroautophagy' is:

**'autophagy' (GO:0006914)**

Macroautophagy (GO:0016236) is a specific type of autophagy where cytoplasmic material is sequestered within double-membrane vesicles called autophagosomes, which then fuse with lysosomes for degradation. It is classified as a child term under the broader autophagy process in the GO hierarchy.",,4.1149680614471436,59,117,True,True,0.8333333333333334,"Perfect! I found the information about 'macroautophagy' in Gene Ontology. Based on the search results, I can see the direct parent term.

## Direct Parent Term of 'Macroautophagy' (GO:0016236)

The direct parent term of **macroautophagy** in Gene Ontology is:

- **autophagy** (GO:0006914)

### Additional Information:

**Macroautophagy (GO:0016236)** is defined as ""The autophagic process that proceeds via the formation of an autophagosome.""

The search results show that while macroautophagy has many ancestors in the ontology hierarchy (including ""catabolic process"", ""metabolic process"", ""cellular process"", ""biological_process"", and ""process utilizing autophagic mechanism""), the only **direct parent** (immediate is-a relationship) is **autophagy** (GO:0006914).

This makes biological sense, as macroautophagy is a specific type of autophagy characterized by the formation of autophagosomes, distinguishing it from other forms of autophagy like microautophagy and chaperone-mediated autophagy.",,17.148284912109375,8,402,14070,52270,mcp__ols__searchClasses,"[{""name"": ""mcp__ols__searchClasses"", ""input"": {""query"": ""macroautophagy"", ""ontologyId"": ""go""}}]",VALUABLE,GO:0006914 (autophagy) is the direct parent of macroautophagy (GO:0016236),"SIMPLE QUERY - Straightforward hierarchy navigation.

Method: OLS4 getAncestors or fetch for GO:0016236

Demonstrates when basic ontology navigation tools suffice.

Verified in example_questions.json question 10."
57,2026-02-01,Currency,What hexameric protein complexes have been structurally characterized?,True,True,False,0.38461538461538464,"Many hexameric protein complexes have been structurally characterized across various functional classes. Here are some notable examples:

## Motor Proteins & ATPases
- **AAA+ ATPases** - Large family including ClpX, ClpB, NSF, p97/VCP (protein unfolding/degradation)
- **Helicases** - DnaB, MCM2-7 complex (DNA replication), Rho termination factor
- **F1-ATPase** - α3β3 hexamer (with γδε subunits) in ATP synthase

## DNA/RNA Processing
- **PCNA** (Proliferating Cell Nuclear Antigen) - DNA sliding clamp (actually a trimer that functions as a pseudo-hexamer ring)
- **RecA/RAD51** - DNA repair and recombination (forms helical filaments, hexameric rings)
- **Gp4 helicase-primase** - Bacteriophage T7 replication

## Chaperones
- **GroEL** - Two stacked heptameric rings (not hexameric, but often mentioned alongside)
- **Heat shock proteins** - Hsp104, ClpB (hexameric AAA+ chaperones)

## Other Functions
- **Glutamine synthetase** - Dodecamer (two stacked hexamers)
- **Propionyl-CoA carboxylase** - Hexameric arrangement
- **Hexokinase** - Can form hexamers in some organisms
- **Benzene dioxygenase** - Hexameric arrangement

## Viral Proteins
- **Portal proteins** - Bacteriophage DNA packaging motors
- **ATPase gp16** - Bacteriophage φ29 DNA packaging

The hexameric architecture is particularly common for ring-shaped molecular machines involved in DNA/RNA processing and protein quality control.",,11.85253119468689,51,450,True,False,0.38461538461538464,"Great! The search found over 11,000 hexameric structures in the PDB. Let me provide you with a comprehensive overview of the structurally characterized hexameric protein complexes:

## Structurally Characterized Hexameric Protein Complexes

The PDB contains **over 11,000 hexameric protein structures**. Here are some notable examples across different functional categories:

### **DNA Replication & Repair**
- **DNA Helicases**: RepA helicase (PDB: 1olo), DnaB helicase (2r5u), replicative helicases (5a9k)
- **RadA protein** from *Methanococcus voltae* (4dc9)
- **RuvB motors**: Holliday junction DNA helicase (8efv, 8efy)

### **Metabolic Enzymes**
- **RuBisCO Form II** from *Rhodopseudomonas palustris* (4lf1, 4lf2) - key enzyme in carbon fixation
- **APS kinase** from *Thiobacillus denitrificans* (3cr8)
- **Bifunctional IspDF** from *Campylobacter jejuni* (1w55, 1w57)
- **Uridine phosphorylase** from *Shewanella oneidensis* (4r2x)
- **Ornithine transcarbamylase** from *Lactobacillus hilgardii* (2w37)

### **ATPases & Motor Proteins**
- **GspE ATPase** from *Vibrio cholerae* (4ksr, 4kss)
- **VPS4 hexamer** (5xmi)
- **RavA hexamer** (4upf)
- **Plasma membrane H+-ATPase** (7vh5, 7vh6, 7ny1)
- **Magnesium chelatase ATPase subunit** (6l8d)

### **Signal Transduction**
- **Human IL-6/IL-6α receptor/gp130 complex** (1p9m)
- **NuMA/LGN hetero-hexamers** (6hc2) - mitotic spindle regulators

### **Immune & Defense Systems**
- **HIV-1 Capsid (CA)** hexamers (3gv2, 3mge)
- **NRC resistosomes** (9cc8, 9fp6) - plant immune receptors
- **Human IgG3 Fc complex** (8btb)
- **Human IgG-Fc hexamer** (9uo5)

### **Redox Enzymes**
- **Bromoperoxidase** from *Ascophyllum nodosum* (5aa6)
- **Copper-containing nitrite reductase** (5zl1)
- **Heme protein HTHP** (2oyy)

### **Chaperones & Protein Quality Control**
- **LonA protease** (5e7s)
- **Hsp70-Hsp40-DafA complex** (9dvi)

### **Other Notable Examples**
- **Annexin XII** hexamer (1aei, 1dm5)
- **Insulin hexamer** (2zp6, 6jr3)
- **HIV-1 Capsid protein** hexamers (3gv2, 3mge)
- **CKS protein** (1cks) - cell cycle regulator
- **Dengue virus NS1 protein** hexamer (8wbe, 8wbd)
- **Hazelnut allergen Cor a 9** (8uai)
- **Z-DNA hexamer** d(CGCGCG) (1woe)

Hexameric assemblies are particularly common in:
- **ATPases and motor proteins** (using their oligomeric state for coordinated ATP hydrolysis)
- **DNA helicases** (forming ring structures that encircle DNA)
- **Metabolic enzymes** (providing allosteric regulation)
- **Immune complexes** (enabling avidity effects)

Would you like more detailed information about any specific hexameric complex or functional category?",,27.24348211288452,9,1168,2206,52262,mcp__togomcp__search_pdb_entity,"[{""name"": ""mcp__togomcp__search_pdb_entity"", ""input"": {""db"": ""pdb"", ""query"": ""hexamer hexameric"", ""limit"": 50}}]",VALUABLE,"Hexameric complexes such as SARS-CoV-2 Spike with ACE2 (7A98), tubulin complexes, and various enzyme oligomers","COMPLEX QUERY requiring biological assembly knowledge.

Databases/Resources: PDB

Knowledge Required:
- pdbx_struct_assembly category for oligomeric state
- oligomeric_count and oligomeric_details properties
- CONTAINS filter for 'hexameric'
- struct category for title/description

Without proper knowledge: Cannot locate biological assembly information.

Verified in pdb_exploration.md Pattern 7 (Biological Assembly Query)."
58,2026-02-01,Currency,Which human kinases have been targeted by drugs in clinical trials?,True,True,True,0.7692307692307693,"Based on my training knowledge, numerous human kinases have been targeted by drugs in clinical trials across various therapeutic areas. Here are the major categories and examples:

## Tyrosine Kinases

**Receptor Tyrosine Kinases (RTKs):**
- **EGFR** (Epidermal Growth Factor Receptor) - gefitinib, erlotinib, osimertinib
- **HER2** - lapatinib, neratinib
- **VEGFR** (Vascular Endothelial Growth Factor Receptor) - sunitinib, sorafenib, pazopanib
- **PDGFR** (Platelet-Derived Growth Factor Receptor) - imatinib, sunitinib
- **FGFR** (Fibroblast Growth Factor Receptor) - erdafitinib, pemigatinib
- **MET** (c-Met) - crizotinib, capmatinib
- **ALK** (Anaplastic Lymphoma Kinase) - crizotinib, alectinib, brigatinib
- **RET** - selpercatinib, pralsetinib
- **ROS1** - crizotinib, entrectinib
- **KIT** - imatinib, sunitinib
- **FLT3** - midostaurin, gilteritinib

**Non-receptor Tyrosine Kinases:**
- **BCR-ABL** - imatinib, dasatinib, nilotinib, bosutinib, ponatinib
- **BTK** (Bruton's Tyrosine Kinase) - ibrutinib, acalabrutinib
- **JAK** (Janus Kinases) - ruxolitinib, tofacitinib, baricitinib
- **SRC family kinases** - dasatinib

## Serine/Threonine Kinases

- **BRAF** - vemurafenib, dabrafenib, encorafenib
- **MEK1/2** - trametinib, cobimetinib, binimetinib
- **CDK4/6** (Cyclin-Dependent Kinases) - palbociclib, ribociclib, abemaciclib
- **mTOR** - everolimus, temsirolimus
- **AKT** - multiple inhibitors in trials
- **PI3K** (Phosphoinositide 3-Kinases) - idelalisib, copanlisib, alpelisib
- **RAF** kinases - sorafenib
- **ROCK** (Rho-associated Kinase) - fasudil
- **Aurora kinases** - multiple inhibitors tested
- **PLK** (Polo-like Kinases) - volasertib
- **CHK1/2** (Checkpoint Kinases) - various inhibitors

## Other Important Kinases

- **PARP** (technically ADP-ribosyltransferases, often grouped with kinase inhibitors) - olaparib, rucaparib, niraparib
- **ATR** (Ataxia Telangiectasia and Rad3-related)
- **ATM** (Ataxia Telangiectasia Mutated)
- **DNA-PK** (DNA-dependent Protein Kinase)

This represents a substantial portion of the human kinome (~540 kinases total), with oncology being the dominant therapeutic area, followed by inflammatory/autoimmune diseases. Many multi-kinase inhibitors target several of these simultaneously.",,14.41219711303711,50,872,True,True,0.8461538461538461,"Excellent! Now I have identified many important kinase drug targets. Let me provide a comprehensive answer based on this data and my knowledge of kinase-targeted therapeutics.

## Human Kinases Targeted by Drugs in Clinical Trials

Based on the ChEMBL database and clinical development data, numerous human kinases have been successfully targeted by drugs in clinical trials. Here are the major categories:

### **Receptor Tyrosine Kinases (RTKs)**

1. **EGFR (Epidermal Growth Factor Receptor)** - CHEMBL203
   - Drugs: Gefitinib, erlotinib, afatinib, osimertinib (approved for lung cancer)

2. **HER2/ErbB2 (Receptor tyrosine-protein kinase erbB-2)** - CHEMBL1824
   - Drugs: Lapatinib, neratinib, tucatinib (breast cancer)

3. **ALK (Anaplastic Lymphoma Kinase)** - CHEMBL4247
   - Drugs: Crizotinib, ceritinib, alectinib, brigatinib (lung cancer)

4. **VEGFR (Vascular Endothelial Growth Factor Receptors)**
   - Drugs: Sunitinib, sorafenib, pazopanib, axitinib (renal cell carcinoma, others)

5. **PDGFR (Platelet-Derived Growth Factor Receptor)** - CHEMBL1913
   - Drugs: Imatinib, sunitinib (often multi-targeted)

6. **FGFR (Fibroblast Growth Factor Receptor)**
   - Drugs: Erdafitinib, pemigatinib, infigratinib (bladder cancer, cholangiocarcinoma)

7. **RET (Proto-oncogene tyrosine-protein kinase receptor)** - CHEMBL2041
   - Drugs: Selpercatinib, pralsetinib (lung cancer, thyroid cancer)

### **Non-Receptor Tyrosine Kinases**

8. **BCR-ABL (Fusion protein)** - CHEMBL6105
   - Drugs: Imatinib, dasatinib, nilotinib, bosutinib, ponatinib (chronic myeloid leukemia)

9. **SRC (Proto-oncogene tyrosine-protein kinase Src)** - CHEMBL267
   - Drugs: Dasatinib, bosutinib (CML, also target SRC family kinases)

10. **BTK (Bruton's Tyrosine Kinase)** - CHEMBL5251
    - Drugs: Ibrutinib, acalabrutinib, zanubrutinib (B-cell malignancies)

11. **JAK (Janus Kinases)** - CHEMBL2363062
    - JAK1/JAK2/JAK3: Ruxolitinib, tofacitinib, baricitinib, upadacitinib (myelofibrosis, rheumatoid arthritis)

### **Serine/Threonine Kinases**

12. **BRAF** - CHEMBL5145
    - Drugs: Vemurafenib, dabrafenib, encorafenib (melanoma, colorectal cancer)

13. **MEK1/2 (MAP kinase kinase)** - CHEMBL2111289
    - Drugs: Trametinib, cobimetinib, binimetinib (melanoma, combined with BRAF inhibitors)

14. **CDK (Cyclin-Dependent Kinases)**
    - CDK4/6: Palbociclib, ribociclib, abemaciclib (breast cancer)

15. **mTOR (Mammalian Target of Rapamycin)** - CHEMBL2842
    - Drugs: Everolimus, temsirolimus (renal cell carcinoma, neuroendocrine tumors)

16. **Aurora Kinases** - CHEMBL3430911
    - Multiple compounds in clinical trials for various cancers

17. **AKT (Protein Kinase B)** - CHEMBL2111353
    - Multiple inhibitors in clinical development

### **Lipid Kinases**

18. **PI3K (Phosphoinositide 3-Kinases)**
    - Drugs: Idelalisib (PI3Kδ), copanlisib, alpelisib (PI3Kα) - various cancers

### **Summary**

Over **50+ distinct human kinases** have been targeted by drugs that have reached clinical trials, with many approved for clinical use. The most successful targets have been in **oncology** (cancer treatment), particularly:
- Receptor tyrosine kinases (EGFR, ALK, VEGFR, etc.)
- Fusion kinases (BCR-ABL)
- Serine/threonine kinases (BRAF, MEK, CDK4/6)

Additionally, kinase inhibitors for **inflammatory and autoimmune diseases** (JAK inhibitors, BTK inhibitors) have also been highly successful.

The ChEMBL database indicates there are **1,700+ kinase-related targets** catalogued for humans, making kinases one of the most extensively studied and successfully targeted protein families in drug discovery.",,145.66546392440796,36,3144,9888,174760,"mcp__togomcp__search_chembl_target, mcp__togomcp__run_sparql, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target, mcp__togomcp__search_chembl_target","[{""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""kinase human"", ""limit"": 50}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""chembl"", ""sparql_query"": ""PREFIX chembl: <http://rdf.ebi.ac.uk/terms/chembl#>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT DISTINCT ?target_label ?max_phase\nWHERE {\n  ?target a chembl:SingleProtein ;\n          chembl:organism <http://identifiers.org/taxonomy/9606> ;\n          chembl:targetCmptXref ?protein .\n  \n  ?protein rdfs:label ?target_label .\n  \n  ?assay chembl:hasTarget ?target .\n  ?activity chembl:hasAssay ?assay .\n  ?molecule chembl:hasActivity ?activity ;\n           chembl:highestDevelopmentPhase ?max_phase .\n  \n  FILTER(REGEX(?target_label, \""kinase\"", \""i\""))\n  FILTER(?max_phase >= 1)\n}\nORDER BY DESC(?max_phase) ?target_label\nLIMIT 100""}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""EGFR kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""BCR-ABL kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""BRAF kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""CDK kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""ALK anaplastic lymphoma kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""JAK kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""VEGFR kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""MEK kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""mTOR kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""PI3K kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""BTK kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""SRC kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""HER2 kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""RET kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""FGFR kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""AKT kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""PDGFR kinase"", ""limit"": 5}}, {""name"": ""mcp__togomcp__search_chembl_target"", ""input"": {""query"": ""Aurora kinase"", ""limit"": 5}}]",VALUABLE,"Human kinase targets with clinical-phase drugs, including various receptor tyrosine kinases and serine/threonine kinases","COMPLEX QUERY requiring target and development phase knowledge.

Databases/Resources: ChEMBL

Knowledge Required:
- bif:contains for 'kinase' target search with relevance scoring
- highestDevelopmentPhase filter
- Human organism filter (Homo sapiens)
- Target entity model

Without proper knowledge: Cannot efficiently search targets or filter by phase.

Verified in chembl_exploration.md Pattern 2."
59,2026-02-01,Precision,What is the clinical significance of the ClinVar variant VCV000017004?,True,False,False,0.3333333333333333,"I don't have access to specific ClinVar variant records in my training data, so I cannot provide details about the clinical significance of VCV000017004 specifically.

To find information about this variant, I recommend:

1. **Visiting ClinVar directly**: Go to https://www.ncbi.nlm.nih.gov/clinvar/ and search for VCV000017004

2. **Information you'll find there**:
   - Clinical significance classification (pathogenic, likely pathogenic, uncertain significance, likely benign, or benign)
   - Associated gene and condition(s)
   - Supporting evidence and submitter information
   - Molecular consequences
   - Allele frequency data if available

3. **Additional resources** that may be linked from ClinVar:
   - dbSNP
   - Gene-specific databases
   - Published literature (PubMed)
   - Other variant databases

If you can share what gene or condition you're interested in, I may be able to provide general information about variants in that context, but for the specific clinical significance determination of this particular VCV accession, you'll need to consult the ClinVar database directly.",,6.599876880645752,54,262,True,True,0.5555555555555556,"## Clinical Significance of ClinVar Variant VCV000017004

**Variant Details:**
- **Accession:** VCV000017004.166
- **Gene:** GJB2 (Gap Junction Beta 2)
- **Variant:** NM_004004.6(GJB2):c.35del (p.Gly12fs)
- **Type:** Deletion (frameshift)
- **Alternative names:** c.35delG, NM_004004.5(GJB2):c.35delG(p.Gly12Valfs)

**Genomic Location:**
- Chromosome 13 (13q12.11)
- GRCh38 position: chr13:20,189,547
- dbSNP ID: rs80338939

**Clinical Significance:**

✅ **Classification: Pathogenic**
- **Review Status:** Reviewed by expert panel (high confidence)
- **FDA Recognized Database:** Yes
- **Last Evaluated:** September 20, 2018

**Associated Condition:**
- **Nonsyndromic genetic hearing loss** (deafness)
  - MedGen: C5680182
  - MONDO: MONDO:0019497
  - Orphanet: 87884
  - OMIM: 121011.0005

**Key Points:**

1. **High Clinical Importance:** This is one of the most common pathogenic variants causing hereditary hearing loss worldwide, particularly in populations of European descent.

2. **Population Frequency:** Present at ~0.24% (0.0024) in the 1000 Genomes Project, making it a relatively common pathogenic variant.

3. **Extensive Evidence:** Supported by 101+ clinical submissions from multiple laboratories and databases worldwide, demonstrating strong consensus about its pathogenicity.

4. **Molecular Effect:** The deletion causes a frameshift mutation starting at glycine 12, leading to a non-functional connexin 26 protein, which is essential for normal hearing function.

This variant is clinically actionable and is commonly included in genetic testing panels for hearing loss. Individuals who are homozygous or compound heterozygous for pathogenic GJB2 variants typically have congenital, bilateral, sensorineural hearing loss.",,27.909382820129395,18,895,3362,105513,"mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_efetch, mcp__togomcp__ncbi_esummary","[{""name"": ""mcp__togomcp__ncbi_esearch"", ""input"": {""database"": ""clinvar"", ""query"": ""VCV000017004"", ""max_results"": 5}}, {""name"": ""mcp__togomcp__ncbi_efetch"", ""input"": {""database"": ""clinvar"", ""ids"": [""17004""], ""rettype"": ""vcv"", ""retmode"": ""xml""}}, {""name"": ""mcp__togomcp__ncbi_esummary"", ""input"": {""database"": ""clinvar"", ""ids"": [""17004""]}}]",CRITICAL,Pathogenic - GJB2 c.35del (most cited pathogenic variant with 80 submitters),"SIMPLE QUERY - Straightforward variant lookup.

Method: Direct SPARQL lookup by VCV accession

Demonstrates when basic accession-based queries suffice.

Verified in clinvar_exploration.md simple queries section."
60,2026-02-01,Precision,What EC number is associated with the Rhea reaction RHEA:10000?,True,False,False,0.0,"I don't have specific information about the Rhea reaction RHEA:10000 in my training data. Rhea is a comprehensive database of expert-curated biochemical reactions, and each Rhea ID corresponds to a specific reaction with associated EC (Enzyme Commission) numbers, but I would need to access the actual Rhea database to tell you which EC number is associated with RHEA:10000 specifically.

To find this information, you would need to look up RHEA:10000 directly in the Rhea database (https://www.rhea-db.org/).",,3.5744190216064453,55,132,True,True,0.5,"Perfect! The Rhea reaction **RHEA:10000** is associated with **EC 3.5.1.50**.

This EC number corresponds to a hydrolase enzyme (class 3) that acts on carbon-nitrogen bonds (subclass 5), specifically in linear amides (sub-subclass 1).",,15.8349449634552,15,432,760,78796,"mcp__togomcp__run_sparql, mcp__togomcp__run_sparql","[{""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\nPREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>\n\nSELECT ?ecNumber\nWHERE {\n  <http://rdf.rhea-db.org/10000> rh:ec ?ec .\n  ?ec rdfs:label ?ecNumber .\n}\n""}}, {""name"": ""mcp__togomcp__run_sparql"", ""input"": {""dbname"": ""rhea"", ""sparql_query"": ""\nPREFIX rh: <http://rdf.rhea-db.org/>\n\nSELECT ?ec\nWHERE {\n  <http://rdf.rhea-db.org/10000> rh:ec ?ec .\n}\n""}}]",CRITICAL,EC 3.5.1.50 (amidase),"SIMPLE QUERY - Straightforward reaction property lookup.

Method: Direct SPARQL lookup of rhea:ec property for RHEA:10000

Demonstrates when basic property lookups suffice.

Verified in rhea_exploration.md simple queries section."
